{"product_id":"asymchem-pestle-analysis","title":"Asymchem PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political shifts, regulatory pressures, and technological trends are reshaping Asymchem’s strategic landscape in our concise PESTLE snapshot. This targeted analysis highlights risks and growth levers investors and strategists need now. Ready-made and actionable, it’s ideal for boardrooms and deal teams. Purchase the full PESTLE to unlock the complete, editable intelligence instantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUS–China trade and geopolitical dynamics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShifts in tariffs, export controls and US–China geopolitical tensions—after bilateral goods trade of about USD 691 billion in 2023—can disrupt Asymchem cross-border projects, tech transfers and supply of critical inputs. The firm may face longer lead times, added compliance checks and pricing pressures. Proactive dual-sourcing and regionalization mitigate supply risk. Transparent client communication preserves confidence amid policy shifts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment healthcare priorities and funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePublic investments in healthcare—including a global vaccine market of about 64 billion USD in 2023—drive CDMO demand for scale and surge capacity. Policy support for domestic manufacturing (reshoring incentives in the US, EU and China) reshapes site selection and capacity allocation. Grants, tax credits and direct procurement lower capital hurdles and speed commissioning. Monitoring national pharma strategies guides targeted growth bets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory diplomacy and alignment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDivergence between FDA, EMA and NMPA expectations affects timelines and costs, given all three are ICH members (19 regulatory members as of 2024) but retain agency-specific requirements. Mutual recognition and harmonization efforts via ICH and PIC\/S (about 54 members in 2024) can streamline inspections and approvals. Asymchem gains measurable advantage by engaging regulators early on global programs. A robust global quality system facilitates multi-agency oversight.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndustrial policy and localization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolicies pushing local API and fill–finish capacity—supported by China’s 14th Five-Year Plan (2021–2025) emphasis on biotech—drive Asymchem’s site selection and partner choices, affect procurement rules and workforce planning, and make alignment with science parks key for fast permits and infrastructure access while balancing global networks sustains resilience.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eLocal content rules shape procurement and hiring\u003c\/li\u003e\n\u003cli\u003eScience parks unlock permits\/infrastructure\u003c\/li\u003e\n\u003cli\u003eSite\/partner choices reflect national biotech priorities\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolitical stability and infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStable governance in China and partner markets underpins utilities, logistics, and permitting vital to GMP operations; disruptions in 2023–24 from regional protests and COVID-19 variants highlighted risks to supply chains and site access.\u003c\/p\u003e\n\u003cp\u003ePolitical unrest can close transport corridors and endanger site safety, so business continuity should mandate backup power, inventory buffers, and alternate routes; location diversification reduces single-country risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBackup power: on-site generators and UPS\u003c\/li\u003e\n\u003cli\u003eInventory buffers: safety stock across sites\u003c\/li\u003e\n\u003cli\u003eAlternate routes: multi-modal logistics\u003c\/li\u003e\n\u003cli\u003eLocation diversification: multi-country manufacturing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical and regulatory strains push CDMO reshoring, dual‑sourcing and early regulator alignment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGeopolitical strain (US–China goods trade ~USD 691bn in 2023) and tariffs\/export controls raise compliance costs, delay cross‑border projects and pressure input pricing, making dual‑sourcing and regionalization essential. Policy support and public healthcare spend (global vaccine market ~USD 64bn in 2023) drive CDMO demand and reshoring incentives. Regulatory divergence (ICH 19 members 2024; PIC\/S ~54 members 2024) increases program complexity; early regulator engagement and robust global quality systems reduce approval risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS–China goods trade 2023\u003c\/td\u003e\n\u003ctd\u003eUSD 691bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal vaccine market 2023\u003c\/td\u003e\n\u003ctd\u003eUSD 64bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eICH members 2024\u003c\/td\u003e\n\u003ctd\u003e19\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePIC\/S members 2024\u003c\/td\u003e\n\u003ctd\u003e~54\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a data-backed PESTLE evaluation of how Political, Economic, Social, Technological, Environmental and Legal forces uniquely impact Asymchem’s region and industry, with actionable, forward-looking insights and ready-to-use formatting to help executives, investors and strategists identify risks, opportunities and funding narratives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eAsymchem PESTLE Analysis distilled into a visually segmented, editable summary that’s easy to drop into presentations or share across teams—using clear language to support rapid alignment, risk discussions, and client-ready deliverables.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech funding cycles and demand volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVenture and public-market funding drive Asymchem’s CDMO pipeline; biotech VC and public financings fell roughly 50% from the 2021 peak into 2023, slowing new program starts and shifting mix toward late-stage or cost-sensitive work. Upcycles raise capacity utilization and pricing power, while flexible capacity and tiered offerings protect throughput and preserve margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency and cost competitiveness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExchange-rate swings—RMB volatility of about 5–6% versus USD across 2023–24—hit revenue and input costs on multi-currency contracts, while Asymchem’s hedging and natural USD offsets helped cap FX-driven margin swings in 2024.\u003c\/p\u003e\n\u003cp\u003eEnergy and solvent inflation (roughly 8–12% pressure across 2023–24) and higher spend on single-use components tightened pricing flexibility; Brent averaged near $85\/bbl in 2024, raising feedstock-linked costs.\u003c\/p\u003e\n\u003cp\u003eOngoing efficiency programs targeted 3–6% unit-cost reductions in 2024, preserving unit economics despite input and FX pressures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClient outsourcing penetration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePharma make-versus-buy decisions drive structural CDMO demand as outsourcing penetration rose to roughly 60% of manufacturing spend by 2024, supporting a global CDMO market ~USD160bn. Rising modality complexity and speed-to-market pressures favor external partners. Winning integrated mandates can boost share-of-wallet 20–30% and increase client stickiness. Broad end-to-end services capture lifetime value from preclinical through commercial.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapacity investment and utilization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCapacity investment for Asymchem requires large capital outlays for reactors, suites and containment, so disciplined ramp plans are essential to protect returns.\u003c\/p\u003e\n\u003cp\u003eUnderutilization erodes ROI while chronic overutilization raises quality risks and schedule delays; phased expansion tied to visible backlog mitigates both.\u003c\/p\u003e\n\u003cp\u003eScenario planning that aligns slot availability with molecule complexity and mix ensures throughput matches commercial demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCapex concentration: reactors, containment, suites\u003c\/li\u003e\n\u003cli\u003eRisk balance: underutilization vs overutilization\u003c\/li\u003e\n\u003cli\u003eMitigation: phased expansion tied to backlog\u003c\/li\u003e\n\u003cli\u003eGovernance: scenario planning by molecule mix\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal supply chain costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFreight rate volatility (container rates fell ~60–70% from 2021 peaks by 2024) plus port congestion and customs delays add several days to lead times and tie up working capital; nearshoring and higher safety stock have cut transit variability by roughly 30–40% in recent industry surveys. Strategic supplier contracts secure 60–80% of critical inputs, while digital visibility can reduce expediting costs by up to 25–30%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFreight volatility: -60–70% since 2021\u003c\/li\u003e\n\u003cli\u003eLead-time drag: days from congestion\/customs\u003c\/li\u003e\n\u003cli\u003eNearshoring\/inventory: ~30–40% less variability\u003c\/li\u003e\n\u003cli\u003eSupplier contracts: secure 60–80% inputs\u003c\/li\u003e\n\u003cli\u003eDigital visibility: -25–30% expediting costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical and regulatory strains push CDMO reshoring, dual‑sourcing and early regulator alignment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBiotech funding fell ~50% from 2021 to 2023, slowing new CDMO programs while outsourcing penetration rose to ~60% supporting a ~USD160bn CDMO market. RMB volatility ~5–6% vs USD and energy\/solvent inflation ~8–12% (Brent ~$85\/bbl in 2024) pressured margins; efficiency programs targeted 3–6% unit-cost cuts. Freight rates down 60–70% since 2021; nearshoring\/inventory cut transit variability ~30–40%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech funding shift\u003c\/td\u003e\n\u003ctd\u003e-50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutsourcing penetration\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO market\u003c\/td\u003e\n\u003ctd\u003e~USD160bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRMB vol (2023–24)\u003c\/td\u003e\n\u003ctd\u003e5–6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnergy\/solvent inflation\u003c\/td\u003e\n\u003ctd\u003e8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrent 2024\u003c\/td\u003e\n\u003ctd\u003e~$85\/bbl\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEfficiency target\u003c\/td\u003e\n\u003ctd\u003e3–6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFreight change\u003c\/td\u003e\n\u003ctd\u003e-60–70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNearshoring benefit\u003c\/td\u003e\n\u003ctd\u003e-30–40% variability\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eAsymchem PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Asymchem PESTLE Analysis document you’ll receive after purchase—fully formatted and ready to use. This screenshot reflects the final content, layout and structure with no placeholders. After payment you’ll instantly download the same professional, ready-to-edit file shown here.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162727395705,"sku":"asymchem-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/asymchem-pestle-analysis.png?v=1762707768","url":"https:\/\/portersfiveforce.com\/products\/asymchem-pestle-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}